How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,645 results for

Pruritus in Pregnancy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1621. Dermatoses of pregnancy. (PubMed)

Dermatoses of pregnancy. 9795584 1998 11 16 2018 11 13 0093-0415 169 4 1998 Oct The Western journal of medicine West. J. Med. Dermatoses of pregnancy. 223-4 Cohen L M LM eng Journal Article United States West J Med 0410504 0093-0415 AIM IM Female Humans Impetigo Pregnancy Pregnancy Complications, Infectious Pruritus Skin Diseases 1998 10 31 1998 10 31 0 1 1998 10 31 0 0 ppublish 9795584 PMC1305293 Arch Dermatol. 1994 Jun;130(6):734-9 8002643 Br J Dermatol. 1997 Jul;137(1):123-9 9274639 Keio J

Full Text available with Trip Pro

1998 Western Journal of Medicine

1622. Dermacase. Pruritic urticarial papules and plaques of pregnancy (PUPPP). (PubMed)

Dermacase. Pruritic urticarial papules and plaques of pregnancy (PUPPP). 9721414 1998 09 14 2009 11 11 0008-350X 44 1998 Aug Canadian family physician Medecin de famille canadien Can Fam Physician Dermacase. Pruritic urticarial papules and plaques of pregnancy (PUPPP). 1609, 1618 Adams S P SP eng Case Reports Journal Article Canada Can Fam Physician 0120300 0008-350X IM Abdomen Adult Diagnosis, Differential Female Humans Pemphigoid Gestationis diagnosis Pregnancy Pregnancy Complications (...) diagnosis Pruritus diagnosis Skin Diseases, Papulosquamous diagnosis Urticaria diagnosis 1998 8 29 1998 8 29 0 1 1998 8 29 0 0 ppublish 9721414 PMC2277735

Full Text available with Trip Pro

1998 Canadian Family Physician

1623. Screening for bacterial vaginosis in pregnancy. (PubMed)

Screening for bacterial vaginosis in pregnancy. Bacterial vaginosis (BV) is a strong independent risk factor for adverse pregnancy outcomes. BV is found in 9% to 23% of pregnant women. Symptoms include vaginal discharge, pruritus, or malodor, but often women with BV are asymptomatic.To determine whether screening and treating pregnant women for BV reduces adverse pregnancy outcomes, as part of an assessment for the U.S. Preventive Services Task Force.Randomized clinical trials of BV treatment (...) in pregnancy that measured pregnancy outcomes were identified from multiple searches in MEDLINE from 1966 to 1999, the Cochrane Controlled Trials Register and Library, and national experts.All randomized controlled trials of BV treatment in pregnancy that specifically measured pregnancy outcomes.The following information was abstracted: study design and blinding, diagnostic methods, antibiotic interventions, timing of antibiotic treatment in pregnancy, criteria for treatment, comorbidities, demographic

2001 American journal of preventive medicine

1624. Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid. (PubMed)

Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid. Cholestasis of pregnancy is associated with increased fetal morbidity and mortality and should be treated actively. The significance attached to pruritus in pregnancy is often minimal, but it is a cardinal symptom of cholestasis of pregnancy, which may have no other clinical features. Eight women with previous cholestasis of pregnancy were referred to The Liver Unit within (...) of these cases with recurrent cholestasis of pregnancy were referred while pregnant. In each, cholestasis developed with severe pruritus, gross increase of serum bile acids, and deranged liver tests. Each was treated with the choleretic agent ursodeoxycholic acid, with rapid clinical improvement and resolution of deranged biochemistry. In conclusion, cholestasis of pregnancy continues to be treated expectantly despite its association with increased morbidity and mortality and evidence suggesting improved

Full Text available with Trip Pro

1995 Gut

1625. Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients. (PubMed)

Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients. Twelve episodes of acute fatty liver of pregnancy (AFLP) were diagnosed in 11 patients during the past 18 years in a general hospital in Santiago, Chile, with a prevalence of 1 per 15,900 deliveries. Acute fatty liver of pregnancy started between the 31st and 38th weeks of pregnancy, with malaise, vomiting, jaundice, and lethargy as the main clinical manifestations. Polydipsia (in nine episodes) and skin pruritus (...) (in seven episodes) were unusual clinical findings. In two patients, pruritus started two and four weeks before AFLP, suggesting that an intrahepatic cholestasis of pregnancy preceded AFLP in those patients. Considering the current prevalence of both diseases in Chile, their association should be considered fortuitous. In another patient, two consecutive pregnancies were affected by AFLP, raising to three the number of reported patients with recurrent AFLP. In 11 episodes, liver biopsies supported

Full Text available with Trip Pro

1994 Gut

1626. Echinococcal Disease of the Liver in Pregnancy (PubMed)

Echinococcal Disease of the Liver in Pregnancy Although echinococcal disease of the liver is common in some parts of the world, it is rarely seen in the United States. Even from endemic areas, few reports deal with its treatment during pregnancy. A 25 year old 18 week pregnant Italian woman presented with pruritus and right upper quadrant pain. Ultrasound revealed a cystic lesion in the left lobe of the liver. The cyst was treated by operative insertion of hypertonic saline and capsulorrhaphy

Full Text available with Trip Pro

1990 HPB Surgery

1627. Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration. (PubMed)

Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration. Previous investigations have indicated that S-adenosyl-L-methionine (SAMe) leads to reversal of estrogen-induced bile flow impairment in rats. This randomized, single-blind clinical trial was performed to determine whether SAMe reverses intrahepatic cholestasis of pregnancy (ICP) which occurs in hypersensitive women associated with increased estrogen levels in late pregnancy (...) to initial levels; opposite results were found in the other two treatment groups. The final values of these selected parameters were lower in the group of subjects treated with 800 mg per day SAMe than in the other two groups of women. Pruritus graded on a 0 to 4+ scale significantly was reduced only in patients treated with the higher dose of SAMe. These results indicate a trend toward remission of ICP in women treated with 800 mg per day SAMe and suggest that SAMe administration may be a new

1984 Hepatology Controlled trial quality: uncertain

1628. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. (PubMed)

S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Previous studies have shown that S-adenosylmethionine (SAMe) counteracts oestrogen-induced bile secretion failure. In order to confirm this anticholestatic activity, we conducted a single-blind clinical trial comparing SAMe with placebo in the treatment of women with intrahepatic cholestasis of pregnancy (ICP). Thirty patients in the last trimester of pregnancy were randomly (...) assigned to receive either SAMe (800 mg/day i.v.) or placebo until delivery for a mean period of 18 days. After SAMe, the women exhibited significantly (p less than 0.01) lower levels of total bile acids, serum conjugated bilirubin and aminotransferases with respect to pretreatment levels as well as to the corresponding values of the placebo group. In addition, SAMe significantly reduced pruritus whereas placebo was ineffective. No adverse reactions on mother or child were recorded during SAMe

1990 Hepato-gastroenterology Controlled trial quality: uncertain

1629. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. (PubMed)

with pruritus that appeared during pregnancy and with elevated serum levels of bile salts (68.1 +/- 15.9 mumol/L; mean +/- S.E.M.) and ALT (226 +/- 50 KU/L) were enrolled in a prospective double-blind study comparing the effects of the drug with a placebo. S-Adenosyl-L-methionine, 900 mg, or placebo was administered in daily intravenous infusions for 20 days. Every 5 days liver function tests were done and pruritus was assessed using a preestablished score. No significant differences in pruritus or in serum (...) levels of bile salts, ALT, bilirubin and alkaline phosphatases were seen during or after treatment between patients who received S-adenosyl-L-methionine (n = 9) or placebo (n = 9). No relevant adverse reactions were detected. Most patients had cesarean sections because of reasons unrelated to the therapeutic trial. All newborns had Apgar scores greater than 7 and normal postnatal development. Our patients had moderately severe to severe cholestasis of pregnancy as indicated by the onset of pruritus

1991 Hepatology Controlled trial quality: uncertain

1630. A clinical trial of hydroxyethylrutosides in the treatment of haemorrhoids of pregnancy. (PubMed)

A clinical trial of hydroxyethylrutosides in the treatment of haemorrhoids of pregnancy. The safety and efficacy of 500 mg O-(beta-hydroxyethyl)rutosides given orally twice daily in the treatment of 97 patients with first-, second-, or third-degree haemorrhoids were investigated in a double-blind, randomized placebo-controlled trial. The rutosides produced a significant (P less than 0.001) improvement in patient-assessed subjective symptoms (pain, bleeding, exudation and pruritus) compared (...) with placebo. There was also a significant (P less than 0.001) improvement in clinician-assessed subjective and objective signs (bleeding, inflammation and dilatation of the haemorrhoidal plexus) after 2 and 4 weeks' treatment compared with placebo. There were three mild, transient side-effects reported in the active treatment group and no drug-related problems in the pregnancy or delivery were observed. The results suggest that O-(beta-hydroxyethyl)rutosides provide a safe and effective treatment

1992 The Journal of international medical research Controlled trial quality: predicted high

1631. Treatment of cholestasis of pregnancy with peroral activated charcoal. A preliminary study. (PubMed)

Treatment of cholestasis of pregnancy with peroral activated charcoal. A preliminary study. Elevated serum bile acid levels may play a role in the symptoms associated with cholestasis of pregnancy. Nineteen women (20 pregnancies) with cholestasis of pregnancy were randomized to receive either activated peroral charcoal (9 women, 10 pregnancies) with a dose of 50 g 3 times a day for 8 days or only normal follow-up (n = 10). Serum total bile acids, aminotransferases, alkaline phosphatase, albumin (...) , total cholesterol, and bilirubin (total and conjugated) were evaluated after overnight fasting at the start of the study and on days 4 and 8 of follow-up. By day 8 of treatment serum total bile acid concentrations were lower in patients of the charcoal group than in the control group (P < 0.05). A decrease of total bile acids was observed in seven patients but in only one of the controls (P < 0.05). No other observations (including pruritus) were changed significantly by charcoal. The outcome

1994 Scandinavian journal of gastroenterology Controlled trial quality: uncertain

1632. S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. (PubMed)

UDCA the women exhibited significantly lower levels of total bile acids (P < 0.02), but no significant differences were noted in AST, ALT, or alkaline phosphatase. All ten patients showed a complete resolution of pruritus. After SAMe no significant changes were noted in pruritus, total bile acids or liver function tests. No adverse reactions on mother or child were recorded during either UDCA or SAMe treatment and the outcome of pregnancy was favorable in both groups.These findings show that UDCA (...) S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. To evaluate the efficacy of S-adenosylmethionine (SAMe) and ursodeoxycholic acid (UDCA) in intrahepatic cholestasis of pregnancy (ICP).Twenty patients in the last trimester of pregnancy were randomly assigned to receive either SAMe (1000 mg/day i.m.) or UDCA (450 mg/day) until delivery; the treatment lasted at least 15 days in all cases.After

1996 European journal of obstetrics, gynecology, and reproductive biology Controlled trial quality: uncertain

1633. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. (PubMed)

Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Intense pruritus and the risk of stillbirths and premature deliveries justify the search for an effective pharmacologic treatment of intrahepatic cholestasis of pregnancy. This study was designed to test the efficacy of ursodeoxycholic acid in maternal pruritus, the biochemical abnormalities and the outcome of pregnancy, in patients with intrahepatic cholestasis (...) of pregnancy of early onset.Pregnant patients hospitalized in a secondary case-referral center with intense pruritus and abnormal serum levels of bile salts and aminotransferases, detected before week 33 of pregnancy, were randomly assigned to receive ursodeoxycholic acid, 1 g per day orally, or an identical placebo, until delivery, in a double-blind study. A 3-week trial period was chosen to compare drug and placebo effects. The follow-up was extended for 3 months after delivery.Twenty-four patients

1997 Journal of hepatology Controlled trial quality: predicted high

1634. [Effects of micronized natural progesterone on the liver during the third trimester of pregnancy]. (PubMed)

[Effects of micronized natural progesterone on the liver during the third trimester of pregnancy]. In France, prescription of micronized progesterone at high doses of 900 to 1200 mg/day is common practice in the case of preterm delivery, even though this is neither an indication nor a posology given for marketing authorisation. A few cases of gestational pruritus have been reported during such use, associated with cholestasic and/or cytolytic hepatic disorders. We report here the results (...) (icterus, pruritus) which could be attributed to gravid cholestasis. We may conclude from this prospective study that, during the third trimester of pregnancy, micronized progesterone is associated with a significant risk of biological cholestasis. This would suggest that in patients genetically predisposed towards gravid cholestasis, micronized progesterone could be a factor favoursing this disease.

1997 Contraception, fertilité, sexualité (1992) Controlled trial quality: uncertain

1635. Trihydroxyethylrutosides in the treatment of hemorrhoids of pregnancy: a double-blind placebo-controlled trial. (PubMed)

Trihydroxyethylrutosides in the treatment of hemorrhoids of pregnancy: a double-blind placebo-controlled trial. The safety and efficacy of Trihydroxyethylrutosides (HR) in the treatment of 53 patients with 1st-2nd degree hemorrhoids of pregnancy (16th-34th week) was investigated in a double-blind randomised, placebo controlled trial. The dosage of Trihydroxyethylrutosides was 1 tablet of 300 milligrams twice daily for the first 2 weeks. If the treatment was successful, the treatment was stopped (...) . If the clinical signs or symptoms still persisted, the treatment was continued for another two weeks using the same dosage and re-evaluated at the end of the fourth week after initial treatment. The parameters for efficacy were symptoms (pain, bleeding, exudation and pruritus) and the objective signs on proctoscopy (bleeding, inflammation and dilatation of the hemorrhoidal venous plexus). The study revealed improvement of symptoms in the study group which was better than in the control group after 2 weeks

2001 Journal of the Medical Association of Thailand = Chotmaihet thangphaet Controlled trial quality: uncertain

1636. The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease

for Study: 18 Years to 90 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Chronic kidney disease with moderate to severe uremic pruritus for longer than 2 months Exclusion Criteria: pregnancy history of photosensitivity photo-aggravated disease Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact (...) The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2007 Clinical Trials

1637. Post Burn Pruritus Study in Patients Undergoing Wound Healing

Inclusion Criteria: Males or females; 18 years or older. Seen in the United States Army Institute of Surgical Research (USAISR) Burn Clinic with healing burn wounds of any percent (%) of total body surface area (TBSA) causing pruritus Stable medical condition Negative pregnancy test and not nursing Able to indicate status of pruritus on a numeric scale Able to understand and read English Exclusion Criteria: Unstable medical condition as determined by attending burn surgeon Prisoner History of allergic (...) Post Burn Pruritus Study in Patients Undergoing Wound Healing Post Burn Pruritus Study in Patients Undergoing Wound Healing - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Post Burn Pruritus Study

2005 Clinical Trials

1638. Review article: pruritus in cholestatic and other liver diseases. (PubMed)

benefit, but their use is not widespread. In addition, the pruritus associated with intrahepatic cholestasis of pregnancy can now be alleviated in many cases by ursodeoxycholic acid. As it also improves foetal outcome, this should become first-line therapy. We review the pathogenesis and therapy of pruritus, highlighting practical aspects to help with patients with seemingly intractable pruritus. (...) Review article: pruritus in cholestatic and other liver diseases. Pruritus is often the most troublesome symptom in patients with chronic liver disease, particularly when cholestasis is a prominent feature. The exact pathogenesis is unknown, but empirical treatment, such as cholestyramine, based on a liver-based origin of pruritus, has been used for many years. Recently, evidence for a central mechanism for pruritus has been obtained and opioid antagonists have been tried clinically with some

2003 Alimentary Pharmacology & Therapeutics

1639. Prophylactic epidural naloxone reduces the incidence and severity of neuraxial fentanyl-induced pruritus during labour analgesia in primiparous parturients. (PubMed)

Naloxone administration & dosage therapeutic use Narcotic Antagonists administration & dosage therapeutic use Pregnancy Prospective Studies Pruritus chemically induced epidemiology prevention & control Severity of Illness Index 2003 11 18 5 0 2004 5 11 5 0 2003 11 18 5 0 ppublish 14617598 10.1007/BF03018748 (...) Prophylactic epidural naloxone reduces the incidence and severity of neuraxial fentanyl-induced pruritus during labour analgesia in primiparous parturients. 14617598 2004 05 10 2013 11 21 0832-610X 50 9 2003 Nov Canadian journal of anaesthesia = Journal canadien d'anesthesie Can J Anaesth Prophylactic epidural naloxone reduces the incidence and severity of neuraxial fentanyl-induced pruritus during labour analgesia in primiparous parturients. 961-2 Okutomi Toshiyuki T Saito Miwako M Mochizuki

Full Text available with Trip Pro

2004 Canadian journal of anaesthesia = Journal canadien d'anesthesie Controlled trial quality: uncertain

1640. The effect of celecoxib on intrathecal morphine-induced pruritus in patients undergoing Caesarean section. (PubMed)

The effect of celecoxib on intrathecal morphine-induced pruritus in patients undergoing Caesarean section. Pruritus associated with intrathecal opioid administration is particularly common in pregnancy. Nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce the severity of this pruritus but have undesirable side effects. The recent development of drugs that can specifically inhibit the cyclooxygenase 2 isoenzyme have become an attractive alternative. This study was designed to evaluate (...) of pain and pruritus between the two groups. Timing of administration, inadequate dosing and possible altered pharmacokinetics in pregnancy may explain the lack of efficacy.

Full Text available with Trip Pro

2004 Anaesthesia Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>